A Controlled, Randomized, Parallel, Multicentre Study to Assess Safety and Tolerability of the Oral Direct Thrombin Inhibitor AZD0837, Given as an Extended-Release Formulation, in the Prevention of Stroke and Systemic Embolic Events in Patients With Atrial Fibrillation.

Trial Profile

A Controlled, Randomized, Parallel, Multicentre Study to Assess Safety and Tolerability of the Oral Direct Thrombin Inhibitor AZD0837, Given as an Extended-Release Formulation, in the Prevention of Stroke and Systemic Embolic Events in Patients With Atrial Fibrillation.

Completed
Phase of Trial: Phase II

Latest Information Update: 14 Jul 2015

At a glance

  • Drugs AZD 0837 (Primary) ; Warfarin
  • Indications Embolism; Stroke; Thromboembolism
  • Focus Adverse reactions; Pharmacodynamics; Pharmacogenomic
  • Sponsors AstraZeneca
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 01 Dec 2009 Results published in European Heart Journal.
    • 29 Aug 2009 Results presented at the Annual Congress of the European Society of Cardiology (ESC-2009)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top